Medical Care in China

Scleroderma (systemic sclerosis)
Treatment in China

Provide a clear and complete coordinated pathway from expert assessment to treatment and rehabilitation.

Get a Care Plan and Cost Estimate
Multidisciplinary consultationsinvolving joint analysis of complex cases by different specialties.
Accurately identify the cause of the diseaseby combining imaging, laboratory and genetic testing.
Tackling complex casesFocusing on Relapsed, Refractory, and Poorly Treated Cases.
Personalized plans aredeveloped based on the patient's actual condition to create a treatment pathway.

Condition Guide

About Scleroderma (systemic sclerosis)

Understand the condition, common triggers and treatment options that may require specialist assessment.

Disease Introduction

Scleroderma, medically known as systemic sclerosis, is an autoimmune disease in which the immune system mistakenly attacks the skin and internal organs, causing the skin to gradually thicken, harden, and tighten. It can also affect the lungs, heart, digestive tract, and blood vessels. Early symptoms often include Raynaud's phenomenon, where the fingers turn white or purple when exposed to cold. With proper treatment, fibrosis can be slowed and vital organs can be protected.


Cutting-edge high-precision diagnostic and treatment technologies

  1. Nintedanib anti-fibrotic : Nintedanib is the first drug approved by the FDA for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The SENSCIS randomized controlled trial has confirmed that it can slow the rate of decline in lung function in patients.
  2. Tocilizumab Biologics : The IL-6 receptor inhibitor tocilizumab has been approved by the FDA for SSc-ILD based on clinical studies, providing a new biologic option for patients with immunosuppressant intolerance or progressive lung disease.
  3. Targeted drugs for pulmonary hypertension : For scleroderma-associated pulmonary hypertension, endothelin receptor antagonists (bosentan, macitentan) and PDE5 inhibitors (sildenafil, tadalafil) are selected according to WHO functional classification, and combination therapy is used when necessary.
  4. Autologous stem cell transplantation : Multiple randomized controlled trials, including ASTIS, have confirmed that autologous hematopoietic stem cell transplantation (AHSCT) is superior to conventional cyclophosphamide in early, rapidly progressing severe diffuse scleroderma and can improve long-term survival.
  5. The 2026 Guideline Update : The Chinese Guidelines for the Diagnosis and Treatment of Systemic Sclerosis (2026 Edition) emphasizes early screening for ILD and pulmonary hypertension, stratified selection of immunosuppressive, antifibrotic, and targeted drugs, and the pursuit of achieving dual targets for scleroderma and pulmonary hypertension.

Care Overview

Scleroderma (systemic sclerosis) Treatment in China

The medical team will develop a personalized protocol based on the pathology type, stage, genetic test, previous treatment history, and the patient's physical condition.

Leading Specialists

Trusted Expertise Across Leading Specialties

Wanping

Associate Chief Physician, Liver Surgery Expert at Renji Hospital.

Rare & Complex Diseases

Research Areas : Pediatric liver transplantation, Kasai procedure for biliary atresia, and complex liver tumor resection, among other pediatric liver surgeries. Cutting-Edge Techniques: Proficient in the surgical treatment of pediatric liver diseases such as biliary atresia, inherited metabolic diseases, cholestasis, and hepatoblastoma, having treated over 1700 cases of various pediatric liver diseases and rare diseases; as a core member of the team, systematically conducting liver transplantation surgery

West China Hospital of Sichuan University logo Affiliated Hospital West China Hospital of Sichuan University
Wu Yu

Chief Physician, Doctoral Supervisor, specializing in rare hematological diseases

Rare & Complex Diseases

Research areas : rare hematological diseases, hereditary hemolytic diseases, systemic amyloidosis - Cutting-edge technologies: Stratified treatment for systemic amyloidosis, molecular diagnostics for complex hematological and rare diseases. - Areas of expertise: Systemic AL amyloidosis, paroxysmal nocturnal hemoglobinuria, hereditary platelet disorders - Academic Highlights: Core expert in multidisciplinary diagnosis and treatment of amyloidosis in China; Core Value: Establishment of individualized drug a

West China Hospital of Sichuan University logo Affiliated Hospital West China Hospital of Sichuan University
Zhang Shuyang

President of Peking Union Medical College Hospital, and concurrently Vice President of the Chinese Academy of Medical Sciences and Peking Union Medical College; Chief Physician, Dr., and Doctoral Supervisor

Rare & Complex Diseases

Deputy Director of the State Key Laboratory of Rare and Complex Diseases; National Health Commission Outstanding Young and Middle-aged Expert, State Council Special Government Allowance Expert, and Changjiang Scholar Dr. appointed by the Ministry of Education. Currently serves as Chairman of the Rare Diseases Branch of the Chinese Medical Association, Chairman of the Rare Disease Diagnosis and Treatment and Guarantee Committee of the National Health Commission, Director of the National Rare Disease Qualit

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences logo Affiliated Hospital Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Shen Min

Doctor of Medicine, Director of the Department of Rare Diseases, Chief Physician of Rheumatology and Immunology, Dr., and Doctoral Supervisor at Peking Union Medical College Hospital.

Rare & Complex DiseasesInternal Medicine

Visiting Scholar at the University of California, San Francisco, and Visiting Researcher in Rheumatology and Immunology at the Cleveland Clinic. Editorial Board Member of the *Chinese Journal of Clinical Immunology and Allergy*, *Chinese Journal of General Practitioners*, and *Peking Union Medical College Journal*. Vice Chairman of the Immunodeficiency Monitoring and Translation Professional Committee of the China Association for the Promotion of Human Health Science and Technology; Standing Committee Mem

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences logo Affiliated Hospital Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Zhang Guojun

Chief Physician, Dr., and Doctoral Supervisor. Currently serves as Director of the Neurology Center, Epilepsy Center, Rare Disease Center, and Neurological Diseases and Cognitive Research Laboratory at the National Children's Medical Center and Beijing Children's Hospital, Capital Medical University.

NeurologyRare & Complex Diseases

Has extensive clinical experience in the surgical treatment of functional neurosurgical diseases, especially refractory epilepsy, and has long been engaged in research on the pathogenesis and intervention strategies of epilepsy and cognitive developmental disorders. Graduated from the Department of Medicine, Hebei Medical University in 1989, and received a Ph.D. in Surgery (Neurosurgery) from Capital Medical University in 2003. Has undertaken more than ten national and provincial-level research projects a

Beijing Children's Hospital (School of Pediatrics, National Children's Medical Center), Capital Medical University logo Affiliated Hospital Beijing Children's Hospital (School of Pediatrics, National Children's Medical Center), Capital Medical University

Patient Stories

See the Next Step Through Patient Journeys

Adult Still's Disease : The End of 120 Days of CASE 01
PATIENT JOURNEY

Adult Still's Disease : The End of 120 Days of "Unexplained High Fever": How a British Pilot Regains His Career in China

Rare & Complex Diseases

Patient records Name: James (pseudonym) Age: 35 Nationality: British Diagnosis: Adult-onset Still's disease (AOSD), characterized by a triad of high fever, rash, and arthritis, accompanied by severe ferritinemia. Treatment Hospital: Department of Rheumatology and Immunology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine For a pilot, any undiagnosed illness means the end of his career. James' nightmare began with what seemed like a common cold, but turned into a 120-day ord

View case details →
IgG4-related disease (involving the pancreas, submandibular gland, and retroperitoneal lymph nodes) - Two years shrouded in CASE 02
PATIENT JOURNEY

IgG4-related disease (involving the pancreas, submandibular gland, and retroperitoneal lymph nodes) - Two years shrouded in "tumor": How a Canadian patient overturned a wrong diagnosis in China.

Rare & Complex Diseases

Patient records Name: Margaret (pseudonym) Age: 61 Nationality: Canadian Diagnosis: IgG4-related disease (involving the pancreas, submandibular gland, and retroperitoneal lymph nodes), previously misdiagnosed as pancreatic cancer. Treatment Hospital: Department of Rheumatology and Immunology, Peking Union Medical College Hospital Case Theme: In the world of intractable diseases, the most agonizing part is often not the treatment itself, but the journey further and further down the path of treatment with a

View case details →

Next Step

Get a Care Plan
and Cost Estimate.

Tell us about your diagnosis and needs, and our team will help screen the right hospital and explain the next steps.

Email:goldentcm@163.com

Get a Care Plan and Estimate

Once you submit your information, a member of our support team will reach out to you within one business day.